A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

NCT05924438 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Delstrigo
DRUG: KOCITAF

Sponsor

Professor Francois Venter

Collaborators

[object Object]
[object Object]